SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

XP Power founder trims holding

Wed, 04th Aug 2010 16:28

XP Power deputy chairman James Peters raised £1.47m from a share disposal two days after bumper interim figures from the power control products supplier. Peters sold 200,000 shares at 735p each. Peters founded XP in 1988 and still owns nearly 2.7m shares, which is equivalent to 14%. That still makes him the biggest shareholder in XP. It was announced yesterday evening that finance director Mickey Lynch had sold 25,000 shares at 730.21p a share. That raised nearly £183,000 and left Lynch with 81,000 shares. Lynch bought 3,500 shares at 372p each and 2,500 shares at 362p each last November. That indicates how strong the XP share price has been in recent months. The share price is more than five times the level it was at the beginning of 2009. XP nearly doubled its pre-tax profit from £3.8m to £7.3m in the six months to June 2010. Revenues were 23% higher at £40.7m and they should continue to improve in the second half. XP Power has record order books.Edison Investment Research says that a higher proportion of own-designed/own-manufactured products has enabled XP to increase its margins. XP is using around 50% of its Chinese capacity and it is planning a factory in Vietnam, which should be in production before the end of 2011. Edison upgraded its 2010 earnings per share forecast by 13% to 62p. That means that the shares are trading on less than 12 times prospective earnings for 2010. Top Director BuysCapital & Counties Properties (CAPC) Director name: Mr Gary YardleyAmount purchased: 88,579 @ 112.05p Value: £99,253Capital & Counties Properties (CAPC) Director name: Mr Ian DurantAmount purchased: 64,024 @ 112.05p Value: £71,739Mid Wynd International Inv Trust (MWY) Director name: Mr Russell Napier Amount purchased: 5,200 @ 960.00p Value: £49,920Filtronic (FTC) Director name: Mr Edwin Graham MeekAmount purchased: 50,000 @ 38.00p Value: £19,000Filtronic (FTC) Director name: Mr Howard FordAmount purchased: 42,204 @ 35.00p Value: £14,771Summit Corporation (SUMM) Director name: Mr Raymond SpencerAmount purchased: 400,000 @ 2.93p Value: £11,720Severn Trent (SVT) Director name: Mr Gordon FryettAmount purchased: 1,000 @ 1,141.00p Value: £11,410Top Director SellsXP Power (XPP) Director name: Mr James E PetersAmount sold: 200,000 @ 735.00p Value: £1,470,000BT Group (BT.A) Director name: Mr Ian LivingstonAmount sold: 72,725 @ 141.99p Value: £103,262BT Group (BT.A) Director name: Mr Tony ChanmugamAmount sold: 19,635 @ 141.99p Value: £27,880

More News

30 Apr 2014 11:55

Summit Corp Loss Widens As Drug Programmes Progress

LONDON (Alliance News) - Drug company Summit Corporation PLC Wednesday said its loss widened in its last financial year as its research and development costs rose as both its drug programmes moved towards clinical trials. The Oxford-based company is currently developing treatments for Duche

18 Mar 2014 13:29

Summit Corporation Gets FDA Approval For Novel Antibiotic Study

LONDON (Alliance News) - Summit Corporation PLC Tuesday said the US Food and Drug Administration has approved its Investigational New Drug application to initiate a Phase 2 proof of concept study for its novel antibiotic SMT19969 for the treatment of C. difficile infection. In a statement,

26 Feb 2014 11:40

Summit Corporation Completes Fund Raising With Over-Subscribed Subscription

LONDON (Alliance News) - Summit Corporation Wednesday said it raised gross proceeds of GBP1.0 million in an oversubscribed subscription offer, meaning it raised GBP22.0 million through its recent placing and the subscription. In a statement, Summit said it had to scale back allocations afte

14 Jan 2014 15:22

Sector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance

Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c

25 Nov 2013 11:52

UK WINNERS & LOSERS: Airlines Soar, Oil Producers Slip After Iran Deal

25 Nov 2013 11:14

Summit Corp Rises As It Enters Alliance With Oxford University

18 Nov 2013 08:10

Monday broker round-up UPDATE

AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation. APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation. Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation

22 Aug 2013 07:25

Thursday broker round-up UPDATE

Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged. Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating. BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendati

3 Jul 2013 09:16

Wednesday broker round-up UPDATE

Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating. ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p. Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves

11 Apr 2013 09:02

Refocused Summit targets new funding

AIM-listed biotech group Summit Corporation has narrowed the focus of its research programmes to two key assets, which both made encouraging progress in clinical trials, the company said. Chief Executive Glyn Edwards, who was appointed in April last year, curtailed other research activities to pre

11 Mar 2013 09:18

Summit study augurs well for Alzheimer's sufferers

Shares in AIM-listed drug development company Summit rose on Monday after the company unveiled encouraging results from a study investigating the impacts of a treatment on neurodegenerative diseases. The company reported that it had presented new data from its OGA (O-linked N-acetylglucosaminidase

13 Feb 2013 13:32

Summit Corp. forms advisory board to aid development of drug

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD). The board will be made up of six

22 Oct 2012 09:40

Summit wins multi-million pound drug funding

Summit, a UK drug discovery company, said it had been awarded four million pounds to support clinical development of a new C. difficult antibiotic The money from charitable foundation the Wellcome Trust will be used to develop Summit's SMT 19969 drug through to clinical proof of concept studies.

10 Oct 2012 09:08

Summit successfully tests muscle dystrophy drug

Shares in drug developer Summit Corporation rocketed on Wednesday after it announced positive results in tests for its new Duchenne Muscular Dystrophy (DMD) drug. DMD is a fatal muscle wasting disease for which there is currently no cure. The firm announced positive top-line results from a Phase 1

11 Sep 2012 09:49

Contract wins round-up: Summit, Pinnacle, Eckoh

UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb. The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summi

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

XP Power founder trims holding

Login to your account

Quickpicks are a member only feature

Login to your account